Back

Invasive haemodynamic assessment shows the obesity-HFpEF phenotype is common amongst patients with symptomatic AF

30 August 2024 (12:00 - 12:40)
Organised by: Logo
Congress Presentation Part of: Risk assessment and prognosis in atrial fibrillation Mechanisms for Heart Failure and Cardiac Complications ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Jonathan Ariyaratnam

University of Adelaide, Adelaide (Australia)

5 More presentations in this session

Presentation thumbnail
The association of NT-proBNP levels in atrial fibrillation patients and 3-year risk of heart hospitalization and death
Doctor K. Szummer (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Ambulatory polygraphy as a screening tool for obstructive sleep apnea in combination with semi-continuous rhythm monitoring in patients with atrial fibrillation: a pilot study
Miss R. Onder (Hasselt, BE)
Abstract Slides Video
Presentation thumbnail
Risk and causes of hospital admission in patients with atrial fibrillation on treatment with oral anticoagulants
Doctor A. Pannunzio (Rome, IT)
Abstract Slides Video
Presentation thumbnail
An external validation of DOAC score in patients with atrial fibrillation following transcatheter aortic valve replacement
Doctor Y. Harano (Gifu, JP)
Abstract Slides Video
Presentation thumbnail
Novel predictor of thrombosis after left atrial appendage closure -Neutrophil to Lymphocyte Ratio (NLR), platelet to LymPhocyte Ratio (PLR), and Lymphocyte to Monocyte Ratio (LMR)-.
Doctor S. Ryuzaki (Chiba, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Risk assessment and prognosis in atrial fibrillation

The Event

Event poster

ESC Congress 2024

30 August 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Atrial fibrillation: obesity matters
thumbnail
Congress Presentation
The obesity phenotype of HFpEF
thumbnail
Congress Presentation
Left atrial remodeling and novel biomarkers in obese patients with heart failure with preserved ejection fraction compared to type-2-diabetics and obese controls: a cardiac magnetic resonance study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources